

## **Minutes: Steering Board Meeting, 7 August 2020**

[REDACTED] verified that all participants attending the meeting had signed the declaration of confidentiality and absence of conflict of interest.

### **1. Update on AstraZeneca and Sanofi contracts**

#### **AstraZeneca**

The discussions with the company are ongoing. AZ submitted an updated contract with the following key changes:

[REDACTED]

The JNT further clarified that the

[REDACTED]

#### **Sanofi/GSK**

Sanofi received [REDACTED], however, at the time of the meeting, the Company had not replied yet. The deadline is on 10 08 23:59.

### **2. Update on ongoing negotiations with vaccine producers**

The Commission and the JNT continue negotiations with companies in view of securing access to portfolio of vaccines with an aim to secure access to a successful vaccine.

#### **BioNTech/Pfizer**

JNT shared the feedback from several discussions with BioNTech/Pfizer. Intensive negotiations are ongoing. The focus of the discussions is [REDACTED] the EU specific procedures and the possibility for [REDACTED]. Several specific and unique requirements put on the table by the companies are likely to trigger additional meetings.

Pfizer presented a proposal for the distribution to each Member State including a solution for specific temperature requirements. The packaging will maintain the temperature of -80°C for at least a week giving enough time to undertake the vaccination programme.

[REDACTED] A scientific presentation by BioNTech/Pfizer was planned [REDACTED] giving an opportunity to Member States experts to meet with BioNTech/Pfizer scientific experts and ask directly questions linked to the vaccine's safety and efficacy.

Member States thanked the JNT for the negotiations efforts, communicated interest in the vaccine and confirmed that the JNT should maintain the position [REDACTED] while continuing the discussions with the BioNTech/Pfizer.

**Tour de table on the interest in collaborating with BioNTech and the estimated quantity of vaccine**

Estimation of doses of the BioNTech vaccine submitted by MS (during the meeting or in writing prior to the meeting) are summarized in the table below. Several MS expressed an interest in the vaccine but had not yet been in a position to communicate number of vaccine regimens.

Member State	Interest for BioNTech (regimens)
Austria	[REDACTED]
Belgium	[REDACTED]
Bulgaria	[REDACTED]
Croatia	[REDACTED]
Cyprus	[REDACTED]
Czech Republic	[REDACTED]
Denmark	[REDACTED]
Estonia	[REDACTED]
Finland	[REDACTED]
France	[REDACTED]
Germany	[REDACTED]
Greece	[REDACTED]
Hungary	[REDACTED]
Ireland	[REDACTED]
Italy	[REDACTED]
Latvia	[REDACTED]
Lithuania	[REDACTED]
Luxembourg	[REDACTED]
Malta	[REDACTED]
Netherlands	[REDACTED]
Poland	[REDACTED]
Portugal	[REDACTED]
Romania	[REDACTED]

Slovakia	
Slovenia	
Spain	
Sweden	
<b>TOTALS</b>	

**Action:**

- **MS to check if the estimates for vaccine regimens included in the table are accurate and communicate to the European Commission each country needs.**

**J&J**

The company develops an adenovirus vaccine. The global production facility is located in [REDACTED]. After [REDACTED] discussions, the J&J [REDACTED] to the negotiations. JNT reported on constrictive developments especially linked to the [REDACTED] and a price per regimen (single dose). The discussions on the [REDACTED] are still ongoing with a view of getting the access to the vaccine as soon as possible ([REDACTED]).

Member States welcomed the developments noting the longstanding experience of J&J in the production of vaccines. MS further acknowledged the outcomes of negotiations stressing that the team should conclude a deal with the company as soon as possible.

**Moderna**

A significant progress has been made in discussions with Moderna [REDACTED]. The discussions on the [REDACTED]. The company still commits to [REDACTED]. JNT expects to receive a revised proposal later in a day. The regulatory approval in the EU is expected [REDACTED].

**Curevac**

The discussions started advancing following several exchanges on the preparation of the offer. However, [REDACTED]. A manufacturing offer form Curevac is now expected.

**Valneva**

First meeting on the offer with representatives of the JNT took place earlier in a week. The company [REDACTED]. The company presented a [REDACTED] however, the Valneva vaccine [REDACTED] available for the EU before [REDACTED]. Valneva will produce active substance [REDACTED].

**Novavax**

MS stressed positive scientific reports on the vaccine and stressed that it should be added to the portfolio. Steering Board gave the JNT a clear mandate to start negotiations with Novavax. The company has production facilities for both vaccines [REDACTED] in the EU (several MS) [REDACTED]. JNT will set up a meeting with Novavax as soon as possible.

[REDACTED]  
A meeting with [REDACTED] and the JNT is scheduled for the following week. IT reported on preliminary exchanges with the company [REDACTED] develops [REDACTED] vaccine [REDACTED]. The company will be able to provide doses to the EU [REDACTED].

**A.O.B**

### **3. Joint Procurement for a large scale vaccination supplies**

A proposal for a JP for large-scale vaccination supplies (syringes, needles) was shared with MS via the Joint Procurement Committee. Several MS expressed interest, however, [REDACTED]. MS were urged to reflect on the vaccination supplies and liaise with counterparts in the Joint Procurement Committee.

### **4. Guidance on vaccination plans**

ECDC will continue to provide guidance on the deployment of vaccines.

### **5. Allocation of vaccine doses**

According to the agreement between the Commission and the MS, vaccine doses will be allocated on a pro rata basis (Eurostat MS population data). The opt-out clause of the contract was again recalled. MS have 5 days to opt out from buying vaccine doses attributed to each Member States.

### **6. Communication**

Steering Board proceedings and the JNT negotiations remain confidential and not available to third parties. [REDACTED]

### **7. Tour de table on update/completion of estimated numbers of people for vaccination**

[REDACTED] stressed that MS should expressed the vaccine needs in regimens and not doses.

**Action:**

- **MS to verify whether country needs compiled in the table below are expressed in regimens and provide feedback to EC.**

<b>Member State</b>	<b>Estimated vaccine regimens</b>
Austria	
Belgium	
Bulgaria	
Croatia	
Cyprus	
Czech Republic	
Denmark	
Estonia	
Finland	
France	
Germany	
Greece	
Hungary	
Ireland	
Italy	
Latvia	
Lithuania	
Luxembourg	
Malta	
Netherlands	
Poland	
Portugal	
Romania	
Slovakia	
Slovenia	
Spain	
Sweden	
<b>TOTALS</b>	